Breaking News

The dynamic duo powering success at Eli Lilly; what to know about a Wegovy heart health study

July 6, 2023
Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky
Molly Ferguson for STAT

STAT+ | With savvy bets, a dynamic duo makes Eli Lilly one of pharma's biggest success stories

Eli Lilly CEO David Ricks and Chief Scientific Officer Daniel S. Skovronsky have worked closely together to power the company to new heights.

By Matthew Herper


STAT+ | What to know about this summer's landmark Wegovy heart health study

This summer, the drugmaker Novo Nordisk will release results from a closely watched study on obesity drugs and cardiovascular health.

By Damian Garde and Andrew Joseph and Elaine Chen


STAT+ | From 'Jeopardy!' to Politico, the PBM ad wars are taking over D.C.

As Congress scrutinizes PBMs' role in shaping high drug prices, lobbying groups are launching aggressive advertising campaigns.

By Simar Bajaj



Adobe

Why depression after traumatic brain injury is distinct — and less likely to respond to standard treatment

There may be a way to first map and then target brain circuits disrupted by traumatic brain injury that lead to a specific form of depression.

By Elizabeth Cooney


Opinion: Biden promised a 'war on cancer' — but declared war on the cure instead

These policies "will harm our ability to develop new treatments for a whole host of diseases," writes PhRMA CEO and President Steve Ubl.

By Stephen J. Ubl


STAT+ | Generic group sues Minnesota over a drug pricing transparency law it calls an "unconstitutional overreach"

The generic trade group argues the Minnesota law is "draconian" and will cause its members "significant economic harm."

By Ed Silverman


University of Pennsylvania hospital complex
Jon Lovette/Alamy

STAT+ | UPenn and St. Luke's have withdrawn from US News' best hospitals list. Will others follow?

The withdrawal of UPenn and St. Luke's from the US News "Best Hospitals" list is sparking a debate about the value of hospital rankings.

By Simar Bajaj


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments